Jocelyn Solis-Moreira

Feature Writer

B.Sc. Integrative Neuroscience, M.Sc. Psychology

Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood. She is adept at translating and summarizing complex study findings in all medical fields with a particular interest in neurodegenerative diseases, cancer research, infectious diseases, and public health. As a freelance writer, her work spans from news articles and feature articles to evergreen explainers across many publications. Her overall goal is to make science accessible for all.

Articles from Jocelyn

Study shows Omicron less severe than Delta among COVID-19 hospitalized patients

New research posted to the medRxiv* preprint server suggests the Omicron variant produces less severe COVID-19 symptoms than earlier severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.

16 Jan 2022

Researchers outline characteristics of Omicron variant immune escape and viral entry into host cells

A new study found that the Omicron variant contains a number of mutations that decrease neutralizing antibody activity and immune escape.

6 Jan 2022

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

New research shows evidence that the Omicron variant is less severe compared to the Delta variant.

6 Jan 2022

After SARS-CoV-2 booster dose memory B cells adapt to Omicron

Memory B cells never forget recurrent viral exposures and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is no exception, according to a new medRxiv* preprint study.

5 Jan 2022

Time since COVID vaccination is a key driver of breakthrough Omicron infections

Published on the preprint medRxiv* server and awaiting peer review, the findings showed that the significant factor behind breakthrough Omicron infections is the timing from vaccination. The time between vaccination and breakthrough infections induced effective or cross-reactive neutralizing antibodies that neutralize Omicron after Alpha or Delta breakthrough infections.

4 Jan 2022

New study on NAbs against SARS-CoV-2 Omicron variant after vaccination or infection

A recent study suggests neutralizing antibody responses against variants of concern, including Omicron, differs significantly between vaccinated and naturally infected individuals. The research, posted to the medRxiv* preprint server, focused on vaccinated individuals who are pregnant — an understudied group in COVID-19 research.

4 Jan 2022

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

An independent study confirms that current and prospective antiviral treatments are effective in inhibiting severe infection from SARS-CoV-2.

4 Jan 2022

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

A new study found that applying pan-sarbecovirus nanobodies shows a strong affinity toward all sarbecovirus clades and neutralized SARS-CoV-2 receptor binding domains

4 Jan 2022

Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

New research suggests convalescent plasma from unvaccinated donors is not effective against the Omicron variant, however, “hybrid” convalescent plasma from donors who recovered from COVID-19 infection and are vaccinated provides considerable antibody protection.

29 Dec 2021

Animal study suggests Omicron is less infectious than previous SARS-CoV-2 strains

A new study suggests the Omicron (B.1.1.529) variant is not as infectious as scientists initially assumed.

29 Dec 2021

Jocelyn Solis-Moreira

Articles from Jocelyn

Study shows Omicron less severe than Delta among COVID-19 hospitalized patients

Researchers outline characteristics of Omicron variant immune escape and viral entry into host cells

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

After SARS-CoV-2 booster dose memory B cells adapt to Omicron

Time since COVID vaccination is a key driver of breakthrough Omicron infections

New study on NAbs against SARS-CoV-2 Omicron variant after vaccination or infection

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

Animal study suggests Omicron is less infectious than previous SARS-CoV-2 strains

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News